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Abstract In this work, a chromatographic method for iden-
tification of volatile organic compounds was compared with
canine recognition. Gas chromatography and mass spec-
trometry (GC–TOF MS) were used for determination of
concentrations of trace gases present in human breath. The
technique enables rapid determination of compounds in
human breath, at the parts per billion level. Linear correlations
were from 0.83–234.05 ppb, the limit of detection was the
range 0.31–0.75 ppb, and precision, expressed as relative
standard deviation (RSD), was less than 10.00 %. Moreover,
trained dogs are able to discriminate breath samples of patients
with diagnosed cancer. We found a positive correlation
between dog indications and the ethyl acetate and 2-pentanone
content of breath (r00.85 and r00.97, respectively). The
methods presented for detection of lung cancer markers in
exhaled air could be used as a potential non-invasive tool for
screening. In addition, the canine method is relatively simple
and inexpensive in comparison with chromatography.
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Introduction
Lung cancer is one of the most common malicious tumours
and one of the main causes of death in developed countries.
The predominant factor that contributes to lung cancer is
smoking, both active and passive, because cigarette smoke
contains over the 200 substances with carcinogenic or mu-
tagenic activity. Exposure to radon, cadmium, arsenic, be-
ryllium, or asbestos is another common cause of the disease.
Lung cancer is classified into two broad groups: small-cell
lung carcinoma (SCLC) (20–25 % frequency of occurrence)
and non-small-cell lung carcinoma (NSCLC) (70–75 %). The
latter category includes adenocarcinomas (25–30 %), squa-
mous cell (30–35 %), and large-cell carcinomas (10–15 %).
The classification takes into account the histological type of
the cancer, the method of treatment, and tumour prognosis
[1–4]. High lung cancer mortality is primarily because of late
diagnosis. Regular screening for early lung cancer symptoms
is a promising way of reducing mortality. Therefore, finding
non-invasive, painless, and easily accessible screening techni-
ques facilitating early diagnosis are important objectives.
Determination of volatile organic compounds (VOCs) in
exhaled breath can provide valuable information about the
condition of human health. Numerous analytical techniques,
for example sensor arrays proton transfer reaction mass
spectrometry (PTR MS), selected ion flow tube mass
spectrometry (SIFT MS), and tunable diode laser absorption
spectroscopy (TLDS), have been used for this approach
[5–14]. However, chromatography mass spectrometry
(GC–MS) is still the most useful [15, 16].
Williams and Church reported cases in which untrained pet
dogs warned their owners about thigh lesions. The lesions
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were later diagnosed as malignant melanoma [17, 18]. These
authors were the first to propose the idea that dogs were able to
detect human cancer on the basis of odour. The dogs sponta-
neously demonstrated persistent interest in their owner’s leg
by sniffing, licking, and trying to bite the lesions off even
through clothing. When the carcinoma lesions were excised,
the dogs showed no further interest in the site. Other papers
report the ability of specially trained dogs to distinguish, on
the basis of odour, samples taken from patients suffering from
cancer from those taken from healthy humans [19]. Thus,
dogs could be used for the detection of different kinds of
neoplastic disease, e.g. melanoma, lung, breast, prostate, or
ovarian cancer [20–23]. Balseiro and Correia hypothesized
that the volatile organic compounds produced by tumours and
detected by dogs are the products of the major histocompati-
bility complex (MHC) genes [24].
Use of sniffer dogs has some advantages compared with
contemporary analytical methods for identification of
VOCs, for example chromatography or mass spectrometry
(GC–MS). Furthermore, dogs’ mobility enables detection in
different sites outside a laboratory. A trained dog’s response
to a detected odour (sitting or lying down) is binary in
character, i.e. in the form of clear-cut yes/no response,
which makes interpretation of the results much simpler.
Use of gas chromatography and mass spectrometry (GC–
MS) for cancer screening may, in practice, be problematic,
not only because of the sampling procedure but also because
of difficult interpretation of the results.
A variable number of VOCs may be identified in the
breath of patients with diagnosed cancer. Some compounds
may be present in different combinations and quantities.
Therefore, use of a single VOC as a cancer marker seems
useless [25–28]. Because several markers in combination
could enable better diagnosis of the disease, sophisticated
methods of multivariate analysis, for example fuzzy logic
have been applied to the results obtained from GC–MS. On
the other hand, black-box technology is a serious drawback
of canine indications in a scent line-up; it is unknown which
single odour or combination of odours dogs respond to.
In this paper, experiments which involved using trained
dogs to detect odour markers of lung cancer in breath
samples are reported. The results obtained by recognition
by dogs are also compared with those obtained by GC–MS.
Experimental
Materials and reagents
Analysis was performed with an Agilent (Waldbronn,
Germany) 7890A gas chromatograph coupled with a Tru-
TOF spectrometer (Leco, St Joseph, USA). The system was
equipped with a CP-Porabond-Q (Agilent) 25 m×0.25 m×
3 μm column. The oven temperature programme was: initial
temperature 40 °C for 2 min, then ramped at 10 °min−1 to
140 °C, then ramped at 5 °min−1 to 270 °C which was
maintained for 5 min. The temperature of the split–splitless
injector was 200 °C. Electron impact (EI) spectra were
acquired in the mass range 30–300m/z; the electron energy
was 70 eV and the acquisition rate was 50 spectra s−1. Both
ion source and transfer-line temperatures were 200 °C.
Collection of chromatographic data was performed by
means of ChromaTOF software (Leco). A carboxen–poly-
dimethylsiloxane-coated fibre (Supelco, Steinheim, Ger-
many) were used for SPME.
All chromatographic standards (aldehydes, alcohols,
hydrocarbons, and ketones) were purchased from Sigma–
Aldrich (Steinheim, Germany).
Breath collection
Breath samples were collected from 44 healthy volunteers
and 29 patients with lung cancer (including 18 people with
SCLC and 11 with NSCLC, all volunteers). Breath samples
were collected in the Collegium Medicum, NCU. The study
was approved by the local ethics commission. In each
patient’s case, a questionnaire on cancer and its stage was
completed. Data such as age, sex, other diseases, prescribed
drugs, smoking habits, and information about previously
consumed meal were also collected.
The alveolar breath samples were collected by means of a
CO2 controlled sampler (Department of Anesthesiology and
General Intensive Care, Innsbruck Medical University, Inns-
bruck, Austria) in 1-L Tedlar bags. Before collection of
breath, all bags were cleaned by flushing with argon gas
and then filled with argon and heated at 60 °C for 12 h to
remove any contamination. A 200-mL sample was then
transferred into a second bag. The SPME fibre was intro-
duced into the bag through a septum and exposed to a
sample. After extraction for 15 min the SPME fibre was
desorbed in the hot GC injection port for 2 min at 200 °C.
Ambient air samples were taken for blank measurement.
Standard preparation
A gaseous standard was prepared by injecting 1 or 3 μL of
liquid compounds into a 1-L glass bulb. The liquid was then
evaporated. The mixture was subsequently diluted in Tedlar
bags filled with nitrogen to obtain concentration in the range
0.3–234 ppb.
Experiments with sniffer dogs
Male dogs (German shepherd mix) that successfully under-
went three-phase training in the scent line-up were used for
lung cancer detection. The dogs were 20-22 months old.
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The experimental procedure and the conditions in
which the dogs were kept were approved by the Local
Ethics Commission for Animal Experimentation in War-
saw. For testing with the use of dogs, breath odour
samples were collected from the same donors and at
the same time as for the GC–MS analysis. The odour
samples for canine training and detection were taken by
exhaling 2 or 3 times through disposable polypropylene
sampling tubes (Defencetek, Pretoria, South Africa)
15 cm long and 3 cm in diameter.
Sniffing testing procedure
To test the samples, the removable inserts were taken out of
the tubes and placed in sterile polypropylene boxes cov-
ered with hole-punched lids to prevent direct contact of a
dog’s nose with the insertion, salivation, etc.
One breath odour sample taken from a patient with lung
cancer was placed in a line-up with four samples from
healthy volunteers (controls). The dogs were taught to indi-
cate the lung cancer sample by the sitting-down response in
front of the sample. The trials with dogs were repeated
approximately 30 times on different days. The positions of
odour samples in the line-up were randomly changed for
every trial. To prevent suggestion of answers to the dogs
during detection, the experimenter was invisible to the dog,
and the dog handler was not aware of the cancer sample
position in the line-up.
Results and discussion
The linearity, precision, and detection limits for determi-
nation of VOCs in human breath are shown in Table 1.
The relative standard deviation (RSD) was in the range
3.3 to 9.5 % for hydrocarbons, alcohols, aldehydes, and
ketones.
Calibration curves were linear for aliphatic hydrocarbons in
the range 0.9–150.0 ppb, for alcohols 1.6–163.5 ppb, for alde-
hydes 1.3–170.4 ppb, for ketones 1.3–166.4 ppb. Regression
coefficients were high, at least 0.991. The lowest LOD values,
obtained for hydrocarbons, varied from 0.31 to 0.49 ppb.
Exhaled air
All the compounds detected in breath samples were com-
pared with ambient air samples, and only those compounds
with concentrations at least 10 % higher than those in
ambient air were reported. Figure 1 shows a chromatogram
obtained from the breath of a lung cancer patient.
The concentration of pentane, which is regarded as an
oxidative stress marker, ranged from 6.8 to 14.3 ppb for
healthy people and from 0.7 to 17.5 ppb for patients with
cancer (Table 2). Furan and its derivatives are regarded as
smoking status markers. 1-Propanol was observed in breath
of patients with cancer at concentrations in the range 4.37–
13.15. This compound might be postulated as a potential
cancer marker in breath [27]. Moreover, 2-propanol was
Table 1 Validation data for
volatile organic compounds
R2, correlation coefficient ;
RSD, relative standard deviation
; LOD, limit of detection ; LOQ,
limit of quantification
Compound Linearity (ppb) R2 RSD (%) LOD (ppb) LOQ (ppb)
Acetone 1.6–166.4 0.991 8.9 0.54 1.62
Acetonitrile 2.3–234.0 0.996 3.4 0.75 2.25
Benzene 1.3–136.7 0.995 4.6 0.43 1.29
Butanal 1.3–135.6 0.997 8.4 0.44 1.32
2-Butanone 1.3–136.5 0.997 3.3 0.45 1.35
Ethyl acetate 0.9–87.8 0.992 4.5 0.32 0.96
Ethylbenzene 1.0–99.8 0.992 4.5 0.32 0.96
Furan 1.6–165.6 0.999 4.9 0.51 1.53
Hexane 1.5–150.0 0.994 3.4 0.48 1.44
2-Methylpentane 0.9–92.6 0.995 9.5 0.31 0.93
3-Methylpentane 0.9–94.1 0.988 9.3 0.32 0.94
Pentane 1.5–150.0 0.998 5.2 0.49 1.47
2-Pentanone 1.3–103.7 0.996 6.2 0.44 1.32
Propanal 1.7–170.4 0.998 7.2 0.52 1.56
1-Propanol 1.6–163.5 0.995 5.1 0.53 1.58
2-Propanol 1.6–159.6 0.998 9.4 0.52 1.57
2-Propenal 1.3–133.9 0.996 6.2 0.44 1.32
Toluene 1.1–114.7 0.991 5.9 0.37 1.11
o-Xylene 1.0–100.1 0.994 4.8 0.33 0.99
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found in healthy and ill people’s breath samples. Also, its
concentrations in exhaled and ambient air were similar.
The original data from VOCs measurement did not meet
the normality assumption of parametric ANOVA and even log
transformation did not managed to produce a normal distribu-
tion for some compounds. Therefore, the alternative non-
parametric ANOVA (Kruskal–Wallis test) was used to verify
the null hypothesis assuming that three studied groups (cancer
patients, control smokers, and control of non-smokers) came
from the same population. This measures the probability that a
random observation from one group is the same as a random
observation from another group. The value of the chi2 test
confirms the significance of an observation obtained in the
Kruskal–Wallis test. For 12 substances the hypothesis of
uniform concentrations of VOCs in patients’ breath and in
that of healthy controls could be rejected. For the compounds
shown in Table 3 the concentrations were significantly lower
in the healthy group than in people with cancer. For butanal, 2-
butanone, ethyl acetate, ethyl benzene, 2-pentanone, 1-
propanol, and 2-propanol the tendency of greater concentra-
tion in the breath of cancer patients than in controls was found
to be significant at P<0.001.
Dog experiments
Detection sensitivity and specificity were calculated by use
of a yes/no response criterion toward each sniffed sample in
the line-up, i.e. at 50 % probability of getting the correct
response by chance. To evaluate differences in dogs’ indi-
cations between cancer and control samples, and the results
obtained from particular dogs, the chi2 test was used.
The dogs indicated correctly the pattern of breath samples
from lung cancer patients with detection sensitivity and spec-
ificity of 82.2 % and 82.4 %, respectively. False positive
indications toward healthy controls amounted to 17.8 % of
trials. The differences between dogs’ indications of cancer
samples vs. controls were highly significant (chi2 0 1056,
P<0.000). There were significant differences between dogs
in detection sensitivity (chi2 0 25.17, d.f. 0 1,P<0.001) but no
significant differences in detection specificity.
Correlation between a dog’s indications and chemical
analysis
The data concerning the dogs’ indications were analysed.
We tried to find the correlation between the VOCs in ex-
haled air and the dogs’ indications. Two data sets, for
control people (N049) and for patients (N029), contained
Fig. 1 GC–TOF MS
chromatogram obtained from a
sample of air exhaled by a
person with lung cancer



























ppb, parts per billion
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the percentage of a dog’s indications and the chosen com-
pounds. For the patients group, positive Pearson’s correla-
tions between the dogs’ indications and the VOCs content of
breath had a significant positive or negative tendency, e.g.
ethyl acetate and 2-pentanone correlated positively with the
dog’s positive indications (r00.85 and r00.97, respective-
ly), whereas for acetonitrile, propanal, and 1-propanol, the
contents were negatively correlated with the dog’s indica-
tions (r0−0.78, r0−0.87, and r0−0.98 respectively). Two
multivariate methods, FA and PCA, were used for data
calculation, separately for the control and patient groups,
with 19 dimensions presenting percentage of the dog’s indi-
cations and 18 for VOCs.
The data for each dimension were standardised within
the individuals and, to obtain a meaningful structure of
the principal components, the number of factors was
finally limited to two. Factor analysis with varimax ro-
tation was conducted as the first method for the datasets.
For the patient group, two factors were essential for the
classification with Eigenvalues larger than unity. These
two factors provided an explanation for over 80 % of the
total variation. The first factor had a positive value of the
loading coefficient for ethanol, isobutane, butane, iso-
prene, pentane, and benzene. Simultaneously, negative
values were obtained for carbon disulfide, 2-butanone,
and toluene. The second factor was associated with a
dog’s indication and the compounds which were not
classified by the first factor.
Analogously to a simple correlation, the signs of loading
explain the role of compounds in the dog’s indications in the
same way as the simple correlations. Hence, the first factor
could be named as indifferent for the dog, whereas the
second factor correlated with the dog’s indications.
Principal-components analysis (PCA) was also used for
the classification to show the relationships between VOCs
and the dog’s indications toward two components.
Figure 2 enables the classification of the compound either
to the first factor or to the second. For the control people two
first factors were essential for classification but explained
only 51 % of the variance. The interpretation of such results
is uncertain.
Table 3 Kruskal–Wallis ANOVA by ranks for three groups (cancer patients, non-smokers, and smokers) with multiple comparisons for VOCs
detected in breath air
VOC Kruskal–Wallis test χ2 P Cancer patients versus control group:
Groups N H P Non-smokers Smokers
Acetone 3 74 7.13 <0.05 10.04 <0.01 ↑ ns
Benzene 3 54 7.80 <0.05 7.96 <0.05 ↑ ns
Butanal 3 62 37.40 <0.001 50.00 <0.001 ↑ ↑ ↑ ↑ ↑ ↑
2-Butanone 3 53 18.43 <0.001 20.75 <0.001 ↑ ↑ ↑ ↑
Ethyl acetate 3 62 37.40 <0.001 50.00 <0.001 ↑ ↑ ↑ ↑ ↑ ↑
Ethylbenzene 3 73 19.53 <0.001 16.61 <0.001 ↑ ↑ ↑ ↑
Furan 3 29 5.45 00.05 6.34 <0.05 ↑ ns
2-Pentanone 3 73 38.89 <0.001 33.97 <0.001 ↑ ↑ ↑ ↑ ↑ ↑
Propanal 3 29 13.39 <0.01 10.31 <0.01 ↑ ↑ ↑ ns
1-Propanol 3 62 36.52 <0.001 44.18 <0.001 ↑ ↑ ↑ ↑ ↑ ↑
2-Propanol 3 65 44.09 <0.001 57.65 <0.001 ↑ ↑ ↑ ↑ ↑ ↑
2-Propenal 3 30 7.15 <0.05 4.80 00.09 ↑ ns
↑, elevated concentration in cancer group compared with control group at P00.05; ↑↑↑ elevated at P00.001
ns, not significant according to two-tailed test for corresponding multiple comparisons treatments versus control
Fig. 2 Compound classification based on dog’s indication: 1, 3-
methylpentane; 2, ethyl acetate; 3, hexane; 4, 2-pentanone; 5, pentane;
6, 2-methylpentane; 7, ethanol; 8, butane; 9, isobutane; 10, benzene;
11, 2-propanol; 12, acetonitrile; 13, propanal; 14, 1-propanol; 15,
carbon disulfide; 16, 2-butanone; 17, toluene
Identification of volatile lung cancer markers 145
It should be mentioned, however, that GC–MS analysis
of particular VOCs does not explain how a mixture of
compounds is perceived by canine olfaction. The odour
signature of cancer that dogs use for discrimination of the
samples may be related to some specific qualitative or
quantitative olfactory impressions produced by a mixture
of VOCs.
Conclusions
Trained dogs are able to discriminate breath samples of
patients with diagnosed cancer disease from those of healthy
donors at a “better than by chance” rate. The canine method
has the following advantages: dog training and testing is
relatively simple and inexpensive in comparison with ana-
lytical equipment application (GC–MS) and detection sen-
sitivity and specificity in relation to pattern samples were
relatively high and easily interpretable. Although it is highly
probable that dogs used specific breath odour to discrimi-
nate samples, it is still unknown which chemical compound
(s) or odour mixture or other stimuli the dogs respond to.
These investigations on parallel applications of GC–TOF
MS and canine scent for the detection of volatile cancer
markers show promise, however, because crucial biomarker
candidates for non-invasive cancer screening might be
found.
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